The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia

International Journal of Geriatric Psychiatry

Volumn 26, Issue 1, 2011, Pages 100-105

  Andersson, M ^a,b   Zetterberg, H ^c   Minthon, L ^a,b   Blennow, K ^c   Londos, E ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Alzheimer's disease; CSF biomarkers; Lewy body disease; MMSE

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; THREONINE;

AGED; ARTICLE; CEREBROSPINAL FLUID LEVEL; COGNITION; CONTROLLED STUDY; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MEMORY; MINI MENTAL STATE EXAMINATION; ORIENTATION; PARKINSON DISEASE DEMENTIA;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; BRIEF PSYCHIATRIC RATING SCALE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; PARKINSON DISEASE; PEPTIDE FRAGMENTS; THREONINE;

EID: 78650315484     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.2496     Document Type: Article

References (29)

1. Aarsland D, Ballard CG, Halliday G,. 2004. Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol 17: 137-145. (Pubitemid 39128223)
2. Ballard CG, Jacoby R, Del Ser T, et al,. 2004. Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with Lewy bodies. Am J Psychiatry 161: 843-849.
3. Bibl M, Mollenhauer B, Esselmann H, et al,. 2006. CSF amyloid-{β}-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 129: 1177-1187.
4. Clark CM, Xie S, Chittams J, et al,. 2003. Cerebrospinal fluid Ï? and {β}-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 60: 1696-1702.
5. Deramecourt V, Bombois S, Maurage CA, et al,. 2006. Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodies. J Neuropathol Exp Neurol 65: 278-288.
6. Edison P, Rowe CC, Rinne JO, et al,. 2008. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11c]PIB-PET. J Neurol Neurosurg Psychiatry 79: 1331-1338.
7. Emre M, Aarsland D, Dag A, Brown R, et al,. 2007. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 22, 1689-1707. (Pubitemid 47597592)
8. Folstein MF, Folstein SE, Mchugh PR,. 1975. 'Mini-Mental State'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
9. Gomez-Tortosa E, Gonzalo I, Fanjul S, et al,. 2003. Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease. Arch Neurol 60: 1218-1222. (Pubitemid 37099626)
10. Hanyu H, Shimizu S, Hirao K, et al,. 2006. Differentiation of dementia with lewy bodies from Alzheimer's disease using mini-mental state examination and brain perfusion SPECT. J Neurol Sci 250: 97-102.
11. Jellinger KA, Wenning GK, Seppi K,. 2007. Predictors of survival in dementia with Lewy bodies and Parkinson dementia. Neurodegener Dis 4: 428-430. (Pubitemid 47557284)
12. Kanemaru K, Kameda N, Yamanouchi H,. 2000. Decreased CSF amyloid {β}42 and normal Ï? levels in dementia with Lewy bodies. Neurology 54: 1875-1876.
13. Kraybill ML, Larson EB, Tsuang DW, et al,. 2005. Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology 64: 2069-2073.
14. Lashley T, Holton JL, Gray E, et al,. 2008. Cortical α-synuclein load is associated with amyloid-β plaque burden in a subset of Parkinson's disease patients. Acta Neuropathol 115: 417-425.
15. Lippa CF, Duda JE, Grossman M, et al,. & For the DLB and PDDWG 2007. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68: 812-819.
16. Mckeith IG, Dickson DW, Lowe J, et al,. and For the Consortium on DLB. 2005. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 65: 1863-1872.
17. Mckeith IG, Galasko D, Kosaka K, et al,. 1996. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47: 1113-1124.
18. Mckeith IG, Perry EK, Perry RH,. 1999. Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Neurology 53: 902.
19. Mckhann G, Drachman D, Folstein M, et al,. 1984. Clinical Diagnosis of Alzheimer's Disease: Report of the Nincds-Adrda Work Group under the Auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.
20. Merdes AR, Hansen LA, Jeste DV, et al,. 2003. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 60: 1586-1590.
21. Mollenhauer B, Bibl M, Wiltfang J, et al,. 2006. Total Ï Protein, Phosphorylated Ï (181p)Protein, β-Amyloid(1-42), and β-Amyloid(1-40) in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies.
22. Mollenhauer B, Cepek L, Bibl M, et al,. 2005. Ï Protein, Ab42 and S-100b protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord 19: 164-170. (Pubitemid 40868045)
23. Parnetti L, Lanari A, Amici S, et al,. 2001. CSF Phosphorylated Ï is a Possible Marker for Discriminating Alzheimer's Disease from Dementia with Lewy Bodies. Phospho-Ï International Study Group
24. Parnetti L, Tiraboschi P, Lanari A, et al,. 2008. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry 64: 850-855.
25. Ala TA, Hughes LF, Kyrouac GA, Ghobrial MW, Elble RJ,. 2002. The mini-mental state exam may help in the differentiation of dementia with Lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry 17, 503-509.
26. Vanderstichele H, De Vreese K, Blennow K, et al,. 2006. Analytical performance and clinical utility of the innotest phospho-Ï181p assay for discrimination between Alzheimer's disease and dementia with Lewy bodies CSF phosphorylated Ï is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Ï International Study Group.
27. Williams MM, Xiong C, Morris JC, Galvin JE,. 2006. Survival and mortality differences between dementia with lewy bodies vs. Alzheimer disease. Neurology 67: 1935-1941.
28. Youden WJ,. 1950. Index for rating diagnostic tests. Cancer 3: 32-35.
29. Zaccai J, Mccracken C, Brayne C,. 2005. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing 34: 561-566. (Pubitemid 41699997)